

2 *Be it enacted by the General Assembly of the Commonwealth of Kentucky:*

3 ➔SECTION 1. A NEW SECTION OF KRS 304.17A-600 TO 304.17A-633 IS
4 CREATED TO READ AS FOLLOWS:

5 (1) *As used in this section:*

6 (a) "Covered health care service" means a health care service furnished or
7 proposed to be furnished to a covered person that is specifically available or
8 included as a covered benefit in the covered person's health benefit plan;

14 (d) "Health care provider" has the same meaning as in KRS 304.17A-005,
15 except for purposes of this section the term includes, if practicing
16 independently any:

17 *1. Licensed clinical alcohol and drug counselor licensed under KRS*
18 *Chapter 309:*

19 **2. Licensed psychologist, licensed psychological practitioner, or certified**
20 **psychologist with autonomous functioning licensed or certified under**
21 **the provisions of KRS Chapter 310:**

1 6. Licensed clinical social worker licensed under KRS Chapter 335;

2 (e) "Health care provider group" means two (2) or more health care providers
3 that provide health care services within an entity that shares a common:

4 1. Group provider number; or

5 2. Tax identification number;

6 (f) "Health care service" has the same meaning as in KRS 304.17A-005,
7 except for purposes of this section the term:

8 1. Includes procedures, treatments, and services rendered by a health
9 care provider as defined in this section; and

10 2. Does not include the provision of prescription drugs;

11 (g) "Interoperability standards" means the technical standards set forth in 45
12 C.F.R. sec. 170.215, as amended;

13 (h) "Participating provider":

14 1. Means a health care provider that has entered into a participating
15 provider contract; and

16 2. Includes a health care provider group if the insurer has elected to
17 offer an exemption to the health care provider group under subsection
18 (4)(b)2. of this section;

19 (i) "Participating provider contract" means a contract between a health care
20 provider, either directly or through a health care provider group, and an
21 insurer for the provision of health care services under a health benefit plan;

22 (j) "Utilization" means the number of claims submitted for a particular health
23 care service under a health benefit plan by a participating provider; and

24 (k) "Value-based care agreement" means a contractual agreement between a
25 health care provider, either directly or through a health care provider
26 group, and an insurer that:

27 1. Incentivizes or rewards the provider based on one (1) or more of the

1 *following:*

a. Quality of care;

b. Safety;

c. Patient outcomes;

d. Efficiency;

e. Cost reduction; or

f. Other factors; and

2. May, but is not required to, include shared financial risk and rewards based on performance metrics.

10 (2) An insurer or its private review agent shall not require a covered person,
11 authorized person, or participating provider to obtain a prior authorization for a
12 particular health care service under a health benefit plan if, at the time the health
13 care service was provided, the provider had a prior authorization exemption for
14 that particular health care service under a program offered under subsection (3)
15 of this section.

16 (3) Every insurer shall offer a program under which a participating provider may
17 qualify for an exemption from the requirement to obtain prior authorization for
18 any covered health care service that requires prior authorization.

19 (4) *The program offered under subsection (3) of this section:*

20 (a) *Shall:*

1. Provide that a participating provider, for an evaluation period established by the insurer or private review agent, receive a prior authorization exemption for a particular health care service if, during the previous evaluation period, the provider met program terms and conditions established by the insurer or private review agent that are not in violation of this section;

2. Not condition a prior authorization exemption upon the provider

1 exceeding a ninety-three percent (93%) approval rate for prior
2 authorization requests submitted by the provider for that health care
3 service during an evaluation period;

4 3. Require the insurer or its private review agent to evaluate, on an
5 annual basis, whether a participating provider qualifies to receive a
6 prior authorization exemption for each covered health care service for
7 which the insurer requires prior authorization;

8 4. Require each annual evaluation required under subparagraph 3. of
9 this paragraph to be conducted on:

10 a. For participating provider contracts that have a performance
11 period of one (1) year, the contract's renewal date; or

12 b. For participating provider contracts that have a performance
13 period of greater than one (1) year, the annual anniversary date
14 of the contract renewal;

15 5. Require an insurer or its private review agent to notify each
16 participating provider that qualifies for a prior authorization
17 exemption within thirty (30) days after conducting the annual
18 evaluation required under subparagraph 3. of this paragraph;

19 6. Require an insurer or its private review agent to make available to a
20 health care provider during the contracting process the requirements
21 that the provider must meet to participate in the program; and

22 7. Comply with any administrative regulation promulgated under KRS
23 304.2-110 for or as an aid to the effectuation of this section; and

24 (b) May:

25 1. Offer a prior authorization exemption for any prescription drug;

26 2. Offer a prior authorization exemption to a health care provider group
27 in lieu of each participating provider practicing within a health care

1 **provider group;**

2 3. Condition a participating provider's eligibility to participate in the
3 program on the provider satisfying one (1) or more of the following:

4 a. The provider has entered into, either directly or through a health
5 care provider group, a value-based care agreement with the
6 insurer;

7 b. The provider has been a participating provider for a minimum
8 period of time established by the insurer or private review agent,
9 except an established minimum period of time shall not be more
10 than one (1) year; or

11 c. *The provider:*

16 4. Provide that a participating provider shall not qualify for a prior
17 authorization exemption for any particular health care service unless
18 the provider's utilization for that health care service during the
19 previous evaluation period meets any utilization requirement
20 established by the insurer or private review agent, except an
21 established utilization requirement shall not:

a. *Require a minimum utilization of more than twenty-four (24); or*

23 b. Impose a maximum utilization of less than one hundred ten
24 percent (110%) of the participating provider's utilization for that
25 particular health care service during the previous evaluation
26 period; and

5. Provide that an insurer or its private review agent may revoke a

1 participating provider's prior authorization exemption for any
2 particular health care service, or suspend or revoke a participating
3 provider's participation in the program, if:

4 a. The insurer or private review agent has evidence that the
5 provider has engaged in fraud or abuse; or
6 b. The provider's utilization meets or exceeds a maximum
7 utilization imposed under subparagraph 4.b. of this paragraph.

8 (5) If an insurer or its private review agent determines that a participating provider is
9 eligible to participate in the program offered under subsection (3) of this section,
10 the insurer or private review agent shall send a notice to the provider that
11 includes:

12 (a) A statement that the provider is eligible to participate in the program; and
13 (b) A list of each health care service that is subject to the elimination of prior
14 authorization requirements under the program.

15 (6) For all forms and notices sent to a participating provider in accordance with this
16 section, or any administrative regulations promulgated under KRS 304.2-110 for
17 or as an aid to the effectuation of this section, the insurer or its private review
18 agent shall:

19 (a) Provide a process for the provider to designate and update the provider's
20 preferred manner for receiving the forms and notices; and
21 (b) Send the forms and notices to the provider in the manner designated under
22 paragraph (a) of this subsection.

23 (7) This section shall not be construed to:

24 (a) Prevent an insurer or its private review agent from requesting a health care
25 provider to provide additional information about a health care service
26 rendered to a covered person; or

27 (b) Require coverage of a noncovered health care service under a covered

1 person's health benefit plan.

2 ➔ SECTION 2. A NEW SECTION OF KRS 304.17A-600 TO 304.17A-633 IS
3 CREATED TO READ AS FOLLOWS:

4 **The commissioner shall:**

5 (1) (a) Submit a written report not later than September 30 of each year to the
6 Legislative Research Commission for referral to the Interim Joint
7 Committees on Banking and Insurance and Health Services relating to
8 prior authorization in the provision of health care benefits under this
9 chapter.

10 (b) The report required under paragraph (a) of this subsection shall include:

11 1. Information relating to the implementation and effectuation of
12 Section 1 of this Act;

13 2. The number of insurers and private review agents offering a program
14 required under Section 1 of this Act;

15 3. The number of providers, by provider group, specialty, and county,
16 participating in one (1) or more programs offered under Section 1 of
17 this Act;

18 4. A list of health care services, which shall include a description and
19 Current Procedural Terminology code for each service, for which
20 exemptions have been granted under the programs required under
21 Section 1 of this Act;

22 5. The number of programs offered under Section 1 of this Act, which
23 shall include:

24 a. The number of programs that grant exemptions for one (1) or
25 more prescription drugs; and

26 b. A list of the drugs for which exemptions are granted under a
27 program reported under subdivision a. of this subparagraph; and

1 6. With respect to any health insurance policy, certificate, plan, or
2 contract required to comply with KRS 304.17A-600 to 304.17A-633:
3 a. A list of all services, procedures, and other treatments, including
4 prescription drugs, that require prior authorization;
5 b. The percentage of prior authorization requests for nonurgent
6 health care services in aggregate and by specific service,
7 procedure, prescription drug, and other treatment:
8 i. That were approved without an extension;
9 ii. For which the review was extended and the request
10 approved; and
11 iii. That were denied, which may include the reason or reasons
12 for the denials;
13 c. The percentage of prior authorization requests for urgent health
14 care services that were:
15 i. Approved; and
16 ii. Denied, which may include the reason or reasons for the
17 denials; and
18 d. The average and median time between submission of a prior
19 authorization request and the prior authorization decision for:
20 i. Nonurgent health care services; and
21 ii. Urgent health care services;
22 (2) Provide the Interim Joint Committees on Banking and Insurance and Health
23 Services with a detailed briefing, upon request, to discuss and explain any report
24 submitted under subsection (1) of this section; and
25 (3) Promulgate any administrative regulation, including an emergency
26 administrative regulation, in accordance with KRS Chapter 13A that the
27 commissioner deems necessary to implement this section.

1 ➤Section 3. KRS 304.17A-605 is amended to read as follows:

2 (1) **(a) Except as provided in paragraph (b) of this subsection,** KRS 304.17A-600,
3 304.17A-603, 304.17A-605, 304.17A-607, 304.17A-609, 304.17A-611,
4 304.17A-613, and 304.17A-615 set forth the requirements and procedures
5 regarding utilization review and shall apply to:

6 **1.[(a)]** Any insurer or its private review agent that provides or performs
7 utilization review in connection with a health benefit plan or a limited
8 health service benefit plan; and

9 **2.[(b)]** Any private review agent that performs utilization review
10 functions on behalf of any person providing or administering health
11 benefit plans or limited health service benefit plans.

12 **(b) Section 1 of this Act sets forth additional requirements for prior**
13 **authorization and shall apply to:**

14 **1. Any insurer or its private review agent that provides or performs**
15 **utilization review in connection with a health benefit plan; and**

16 **2. Any private review agent that performs utilization review functions on**
17 **behalf of any person providing and administering health benefit plans.**

18 (2) Where an insurer or its agent provides or performs utilization review, and in all
19 instances where internal appeals as set forth in KRS 304.17A-617 are involved, the
20 insurer or its agent shall be responsible for:

21 (a) Monitoring all utilization reviews and internal appeals carried out by or on
22 behalf of the insurer;

23 (b) Ensuring that all requirements of KRS 304.17A-600 to 304.17A-633 are met;

24 (c) Ensuring that all administrative regulations promulgated in accordance with
25 KRS 304.17A-609, 304.17A-613, and 304.17A-629 are complied with; and

26 (d) Ensuring that appropriate personnel have operational responsibility for the
27 performance of the insurer's utilization review plan.

1 (3) A private review agent that operates solely under contract with the federal
2 government for utilization review or patients eligible for hospital services under
3 Title XVIII of the Social Security Act shall not be subject to the registration
4 requirements set forth in KRS 304.17A-607, 304.17A-609, and 304.17A-613.

5 ➔Section 4. KRS 304.17A-611 is amended to read as follows:

6 (1) A utilization review decision shall not retrospectively deny coverage for health care
7 services provided to a covered person when prior approval has been obtained from
8 the insurer or its designee for those services, unless the approval was based upon
9 fraudulent, materially inaccurate, or misrepresented information submitted by the
10 covered person, authorized person, or the provider.

11 (2) An insurer of a health benefit plan shall not require or conduct a prospective or
12 concurrent review for a prescription drug:

13 (a) That:

14 1. Is used in the treatment of alcohol or opioid use disorder; and

15 2. Contains Methadone, Buprenorphine, an opioid antagonist, or
16 Naltrexone; or

17 (b) That was approved before January 1, 2022, by the United States Food and
18 Drug Administration for the mitigation of opioid withdrawal symptoms.

19 (3) Notwithstanding any other law to the contrary:

20 (a) An insurer or its private review agent shall not conduct a retrospective
21 review that is based solely on a participating provider having a prior
22 authorization exemption under a program offered under subsection (3) of
23 Section 1 of this Act except to determine if the provider continues to qualify
24 for the exemption; and

25 (b) The timeframes for rendering a utilization review decision under KRS
26 304.17A-607 shall not apply to a retrospective review conducted for the
27 purpose of determining if a participating provider qualifies for an initial or

1 continuing prior authorization exemption under a program offered under
2 subsection (3) of Section 1 of this Act.

3 ➔ SECTION 5. A NEW SECTION OF KRS CHAPTER 205 IS CREATED TO
4 READ AS FOLLOWS:

5 *The commissioner of the Department for Medicaid Services shall:*

6 *(1) (a) Submit a written report not later than September 30 of each year to the*
7 *Legislative Research Commission for referral to the Interim Joint*
8 *Committees on Banking and Insurance and Health Services relating to*
9 *prior authorization in the provision of Medicaid benefits in Kentucky.*

10 *(b) The report required under paragraph (a) of this subsection shall include the*
11 *following, categorized by Medicaid managed care organization and fee for*
12 *service:*

13 *1. A list of all services, procedures, and other treatments, including*
14 *prescription drugs, that require prior authorization;*

15 *2. The percentage of prior authorization requests for nonurgent health*
16 *care services in aggregate and by specific service, procedure,*
17 *prescription drug, and other treatment;*

18 *a. That were approved without an extension;*

19 *b. For which the review was extended and the request approved;*
20 *and*

21 *c. That were denied, which may include the reason or reasons for*
22 *the denials;*

23 *3. The percentage of prior authorization requests for urgent health care*
24 *services that were:*

25 *a. Approved; and*

26 *b. Denied, which may include the reason or reasons for the denials;*
27 *and*

1 4. *The average and median time between submission of a prior*
2 *authorization request and a prior authorization decision for:*
3 a. *Nonurgent health care services; and*
4 b. *Urgent health care services;*

5 (2) *Provide the Interim Joint Committees on Banking and Insurance and Health*
6 *Services with a detailed briefing, upon request, to discuss and explain any report*
7 *submitted under subsection (1) of this section; and*

8 (3) *Promulgate any administrative regulation, including an emergency*
9 *administrative regulation, in accordance with KRS Chapter 13A that the*
10 *commissioner deems necessary to implement this section.*

11 ➔ Section 6. KRS 205.536 is amended to read as follows:

12 (1) *Except as provided in subsection (4) of this section,* a Medicaid managed care
13 organization shall have a utilization review plan, as defined in KRS 304.17A-600,
14 that meets the requirements established in 42 C.F.R. pts. 431, 438, and 456. If the
15 Medicaid managed care organization utilizes a private review agent, as defined in
16 KRS 304.17A-600, the agent shall comply with all applicable requirements of KRS
17 304.17A-600 to 304.17A-633.

18 (2) In conducting utilization reviews for Medicaid benefits, each Medicaid managed
19 care organization shall use the medical necessity criteria selected by the Department
20 of Insurance pursuant to KRS 304.38-240, for making determinations of medical
21 necessity and clinical appropriateness pursuant to the utilization review plan
22 required by subsection (1) of this section.

23 (3) To the extent consistent with the federal regulations referenced in subsection (1) of
24 this section, the Department for Medicaid Services or any managed care
25 organization contracted to provide Medicaid benefits pursuant to KRS Chapter 205
26 shall not require or conduct a prospective or concurrent review, as defined in KRS
27 304.17A-600, for a prescription drug:

7 (4) This chapter shall not be construed to require, with respect to the administration
8 and provision of Medicaid benefits pursuant to this chapter, the Department for
9 Medicaid Services, any managed care organization contracted to provide
10 Medicaid benefits pursuant to this chapter, including any private review agent
11 utilized by the Medicaid managed care organization, or the state's medical
12 assistance program to comply with Section 1 of this Act.

13 ➔Section 7. Sections 1 to 4 of this Act apply to contracts delivered, entered,
14 renewed, extended, or amended on or after January 1, 2028.

15 ➔Section 8. Section 5 of this Act takes effect January 1, 2027.

16 ➔Section 9. Sections 1, 2, 3, 4, 6, and 7 of this Act take effect January 1, 2028.